Abstracts tagged "Late-Breaking 2025"

Abstract Number: LB01 • ACR Convergence 2025
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Xia Zhang¹, Ruiling Feng¹, Zhanguo Li² and Jing He¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose Interleukin-2 (Ld-IL2) has shown therapeutic effect in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Various doses from 0.33 to 3.0 million units of…
Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Sitian Zang¹, Ranran Yao¹, Yan Wang¹, Danxue Zhu¹, Jing He¹ and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…
Abstract Number: LB02 • ACR Convergence 2025
Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial
Xi Xu¹, Huaqun Zhu² and Hua Ye¹, ¹Peking University People‘s Hospital, Beijing, China (People's Republic), ²Peking University People‘s Hospital, Beijing, Beijing, China (People's Republic)
Background/Purpose: To evaluate the efficacy of tofacitinib combined with glucocorticoids (GCs) compared with GCs monotherapy in preventing relapse in patients with IgG4-related disease (IgG4-RD).Methods: Compared with glucocorticoid…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Leslie Crofford¹, Dana Dailey², Barbara Van Gorp², Carol Vance², Andrew Post³, Ruth Chimenti², Ezgi Yarasir², Elizabeth Johnson¹, Kari Vance², Bridget Zimmerman², Fangfang Jiang², David-Erick Lafontant², Maxine Koepp², Dixie Ecklund², Emine Bayman² and Kathleen Sluka², ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²University of Iowa, Iowa City, Iowa, ³Grand Valley State University, Grand Rapids, Michigan
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB20 • ACR Convergence 2025
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Désirée van der Heijde¹, Philip Mease², Carle Paul³, Frank Behrens⁴, Laure Gossec⁵, Yuko Kaneko⁶, Lihi Eder⁷, Laura Coates⁸, Andrew Pink⁹, Weiguo Wan¹⁰, Enrique Soriano¹¹, Piotr Leszczyński¹², Jose Scher¹³, Atul Deodhar¹⁴, Chahin Pachai¹⁵, Janice Li¹⁶, Xue Fan¹⁶, Sahar Rabbat¹⁶, Caroline Sardinas¹⁷, Michael Plewinski¹⁸, John Vaile¹⁹ and Joseph Merola²⁰, ¹Leiden University Medical Center, Meerssen, Netherlands, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ³Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, France, ⁴Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁵Sorbonne Université, AP-HP & EULAR, Paris, France, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁷University of Toronto, Toronto, Ontario, Canada, ⁸University of Oxford, Oxford, United Kingdom, ⁹St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom, ¹⁰Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Department of Internal Medicine and Metabolic Disorders, Poznań University of Medical Sciences, Poznań, Poland, ¹³New York University School of Medicine, New York, New York, ¹⁴Oregon Health & Science University, Portland, Oregon, ¹⁵Bristol Myers Squibb, Princeton, New Jersey, ¹⁶Bristol Myers Squibb, Princeton, ¹⁷Bristol Myers Squibb, garwood, New Jersey, ¹⁸Bristol Myers Squibb, Green Brook Township, New Jersey, ¹⁹Bristol Myers Squibb, Warren, New Jersey, ²⁰UT Southwestern Medical Center, Dallas, Texas
Background/Purpose: Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor being investigated in active PsA in the global, randomized, double-blind, placebo (PBO)-controlled, phase 3…
Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
Abstract Number: LB21 • ACR Convergence 2025
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Flore Castellan¹, Griffen Mustion², Mei-Kay Wong¹, Kimberly Johansson², Scott Goldberg¹, Yazan Madanat³, Namrata Chandhok⁴, Abhay Singh⁵, David Sallman⁶, Jane Churpek⁷, Curtis Lachowiez⁸, Jennifer Yannucci⁹, Luke Fletcher¹⁰, Matthew Schwede¹¹, Amber Afzal², Yael Kusne¹², Alejandro Marinos¹³, Alexander Coltoff¹⁴, Rickey Myhand¹⁵, Kiran Vij², Rosalyn Marar¹⁶, Hannah Mitchell², Maria Stoentcheva², Giulia Petrone², Kyra Ddungu², Hannah Hartman², Ryan Monahan², Karen Vandervort², Jie Liu², John Cole², Tibor Kovacsovics¹⁷, Hetty Carraway¹⁸, Tian Zhang¹⁹, Stephen Chung³, Geoffrey Uy², Eytan Stein²⁰, Devendra Hiwase²¹, Matthew Walter², Mrinal Patnaik¹⁶, Kelly Bolton²² and David Beck¹, ¹New York University School of Medicine, New York, New York, ²Washington University School of Medicine, Saint Louis, Missouri, ³UT Southwestern Medical Center, Dallas, Texas, ⁴University Miami Miller School of Medicine, Miami, Florida, ⁵Cleveland Clinic, Cleveland, Ohio, ⁶Moffitt Cancer Center, Tampa, Florida, ⁷University of Wisconsin School of Medicine, Madison, Wisconsin, ⁸Oregon Health & Science University, Portland, Oregon, ⁹Low Country Cancer Care, Savannah, Georgia, ¹⁰Willamette Valley Cancer Institute and Research Center, EUgene, Oregon, ¹¹Swedish Health Services, Seattle, Washington, ¹²Mayo Clinic, Phoenix, Arizona, ¹³UTSouthwestern Medical Center, Dallas, Texas, ¹⁴Medical University of South Carolina, Charleston, South Carolina, ¹⁵CovenantOntology & Hematology, Frankfort, Kentucky, ¹⁶Mayo Clinic, Rochester, Minnesota, ¹⁷City of Hope, Goodyear, Arizona, ¹⁸Case Western Reserve University, Cleveland, Ohio, ¹⁹Stanford Medicine, Stanford, California, ²⁰Memorial Sloan Kettering Cancer Center, New York, New York, ²¹Adelaide Medical School, Adelaide, South Australia, Australia, ²²Washington University School of Medicine, Saint Louis, Minnesota
Background/Purpose: Recently, somatic mutations in hematopoietic stem and progenitor cells (HSPCs) have been proposed as a novel mechanism driving systemic inflammation. UBA1 somatic variants in…
Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB22 • ACR Convergence 2025
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Andreas Reiff¹, Tadej Avcin², Bernd Jilma³, Peter Korosec⁴, Matthias Weiss-Tessbach³, Christian Schoergenhofer³, Masa Bizjak⁵, Barbara Jenko Bizjan⁶, Barbara Cugalj Kern⁵, Kim Simpfendorfer⁷, Christian Lood⁸, Tyler Artner⁹, Angelene Prasanna¹, Ken Olivier¹, Ghazaleh Gouya¹, Ralph Lambalot⁹, Abdul Hakkim¹ and Tobias Fuchs¹, ¹Neutrolis, Cambridge, Massachusetts, ²University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Medical University of Vienna, Vienna, Austria, ⁴University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, ⁵University Medical Center Ljubljana, Ljubljana, Slovenia, ⁶University of Ljubljana, Ljubljana, Slovenia, ⁷Feinstein Institutes for Medical Research, Manhasset, New York, ⁸University of Washington, Seattle, Washington, ⁹Neutrolis, Cambridge
Background/Purpose: Excessive formation and impaired clearance of Neutrophil Extracellular Traps (NETs) have been linked to autoimmune and inflammatory diseases, notably systemic lupus erythematosus (SLE). DNASE1-like…
Abstract Number: LB07 • ACR Convergence 2025
Adipose-Tissue Derived Mesenchymal Stem Cells vs Hyaluronic Acid in Refractory Knee Osteoarthritis in a low-resource setting: A Phase IIb RCT
Moshiur Rahman Khasru¹, Mohammad Tariqul Islam², AGM Zakaria Nazimuddin Jubery³, Mahbuba Shirin⁴, Fazle Rabbi Chowdhury⁵, Tangila Marzen⁶, Nafi Uzzaman⁷, Md Abu Bakar Siddiq⁸, Md Ashraful Hoque⁹, Masuda Begum¹⁰, Md Moniruzzaman Khan² and Abul Salek¹¹, ¹Musculoskeletal Medicine and Interventional Physiatry Division, Bagladesh Medcial University, Dhaka, Bangladesh, ²Department of Physical Medicine and Rehabilitation, Bangladesh Medical University, Dhaka, Bangladesh, ³Department of Burn and Plastic Surgery, Dhaka Medcial College and Hospital, Dhaka, Bangladesh, ⁴Department of Radiology and Imaging, Bangladesh Medical University, Dhaka, Bangladesh, ⁵Department of Internal Medicine, Bangladesh Medical University, Dhaka, Bangladesh, ⁶Department of Anatomy, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh, ⁷Stem Cell Rearch Group, Department of Physical Medicine and Rehabilitation, Bangladesh Medical University, Dhaka, Bangladesh, ⁸Department of Rheumatology, Royal North Shore Hospital, Faculty of Medicine, University of Sydney, New South Wales, Australia, ⁹Department of Transfusion Medicine, Cumilla Medical College, Cumilla, Bangladesh, ¹⁰Department of Haematology, Banglabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, ¹¹Department of Physical Medicine and Rehabilittaion, Bangladesh Medical University, Dhaka, Bangladesh
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability, with no available disease-modifying treatments. While Hyaluronic Acid (HA) remains widely used, there is little…
Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: LB08 • ACR Convergence 2025
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Philip Mease¹, Frank Behrens², Alan Kivitz³, Edit Drescher⁴, Piotr Klimiuk⁵, Howard Sofen⁶, Nehad Soloman⁷, Shephard Mpofu⁸, Fredrik Frejd⁹ and Peter Taylor¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ²Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ³Altoona Arthritis and Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, ⁴Vital Medical Center Rheumatology, Veszprém, Hungary, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, California, ⁷Midwestern University Arizona College of Osteopathic Medicine and Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, ⁸ACELYRIN, INC., Agoura Hills, California, ⁹Affibody Medical AB, Solna, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is a chronic, systemic, inflammatory musculoskeletal disease in which dysregulated IL-17A activity plays a pivotal role in disease pathogenesis. Izokibep (IZO) is an…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].